Arqule Inc. (ARQL)

Trade ARQL now with
2/7/2018 7:03:13 AM Roivant Sciences And ArQule Enter License Agreement For Derazantinib In China
2/2/2018 7:29:38 PM B. Riley FBR Starts ArQule Inc. (ARQL) At Buy With $3 Price Target
11/21/2017 7:01:13 AM ArQule Announces Dosing In A Registrational Trial Of FGFR Inhibitor, Derazantinib, For Intrahepatic Cholangiocarcinoma
11/9/2017 7:01:40 AM ArQule Q3 Net Loss $6.67 Mln Or $0.09/Shr Vs Loss Of $5.82 Mln Or $0.08/Shr Last Year
11/8/2017 7:00:31 AM ArQule Announces $9.5 Mln Private Placement Of Preferred Stock
11/1/2017 7:03:20 AM FDA Grants Rare Pediatric Disease Designation To ArQule’s Miransertib (ARQ 092) For Treatment Of Proteus Syndrome
10/16/2017 7:01:12 AM ArQule Announces $15.7 Mln Private Placement Of Common Stock
8/4/2017 7:01:19 AM ArQule Q2 Net Loss $7.2 Mln Or $0.10/Shr Vs Loss Of $5.1 Mln Or $0.07/Shr Last Year
7/11/2017 7:01:04 AM ArQule Announces First Patient Dosed In Phase 1 Trial Of ARQ 531 For B-cell Malignancies
6/23/2017 7:01:14 AM ArQule Presents Preclinical Data For BTK Inhibitor, ARQ 531
6/7/2017 7:02:35 AM ArQule Unveils First Patient Dosed In Sponsored Phase 1/2 Trial Of AKT Inhibitor, ARQ 092, For Rare Overgrowth Disease
6/3/2017 10:32:49 AM ArQule Presents Phase 1/2 Clinical Data With ARQ 087 In Intrahepatic Cholangiocarcinoma At ASCO Annual Meeting
5/18/2017 6:01:59 AM ArQule To Present Preclinical Data For ARQ 531 In Diffuse Large B-cell Lymphoma In Vitro And In Vivo Tumor Models